Hypoxia in prostate cancer: a powerful shield against tumour destruction?

L Marignol, M Coffey, M Lawler, D Hollywood, Mark Lawler

Research output: Contribution to journalArticlepeer-review

97 Citations (Scopus)


Tumour hypoxia is progressively emerging as a common feature of prostate tumours associated with poor prognosis. While the molecular basis of disease progression is increasingly well documented, the potential role of hypoxia in these processes remains poorly evaluated. By dissecting the impact of hypoxia-inducible factor 1 alpha on molecular responses, this review provides evidence for a powerful protecting role of oxygen deprivation against oxidative stress injury, androgen deprivation, chemotherapeutic and radiation cytotoxicity. We propose hypoxia as a potent tumour-induced shield against destruction and suggest its targeting may need to be routinely addressed in the management of prostate cancer.

Original languageEnglish
Pages (from-to)313-27
Number of pages15
JournalCancer treatment reviews
Issue number4
Publication statusPublished - Jun 2008


  • Androgens
  • Apoptosis
  • Biological Markers
  • Cell Hypoxia
  • Disease Progression
  • Drug Resistance, Neoplasm
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Male
  • Models, Biological
  • Prostatic Neoplasms
  • Reactive Oxygen Species


Dive into the research topics of 'Hypoxia in prostate cancer: a powerful shield against tumour destruction?'. Together they form a unique fingerprint.

Cite this